The FDA has granted accelerated approval for iptacopan, a pioneering complement inhibitor designed to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. This drug targets the alternative complement pathway, which is believed to contribute to the development of IgAN. The approval is based on interim results from the Phase III APPLAUSE-IgAN study, showing a 44% reduction in proteinuria compared to a 9% reduction with placebo.
However, it is not yet confirmed whether iptacopan slows kidney function decline, and ongoing studies will determine its long-term effectiveness and safety. The study demonstrated that iptacopan achieved a statistically significant reduction in proteinuria, and the results were consistent across various patient subgroups. Side effects The drug's safety profile was favorable, with common side effects…
